NCT00648973

Brief Summary

The study was to determine if the drug worked to relieve nasal congestion experienced by people with seasonal allergies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,021

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Nov 2006

Shorter than P25 for phase_4

Geographic Reach
1 country

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2006

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2007

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

March 20, 2008

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 1, 2008

Completed
Last Updated

August 22, 2011

Status Verified

August 1, 2011

Enrollment Period

6 months

First QC Date

March 20, 2008

Last Update Submit

August 19, 2011

Conditions

Keywords

Seasonal Allergic Rhinitis, nasal congestion

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in the subject's mean reflective nasal congestion/stuffiness symptom score

    every 12-hours over the 14-day treatment period

Secondary Outcomes (19)

  • Change from baseline in the subject's mean reflective Total Nasal Symptom (TNS) Score

    14 Days

  • Change from baseline in the subject's mean instantaneous TNS Score

    14 Days

  • Change from baseline in the subject's mean reflective Total SAR Symptom (TSS) Score

    14 Days

  • Change from baseline in the subject's mean instantaneous TSS Score

    14 Days

  • Change from baseline in the subject's mean reflective score for each of the seven remaining individual SAR symptoms, excluding nasal congestion/stuffiness

    14 Days

  • +14 more secondary outcomes

Study Arms (3)

1

EXPERIMENTAL

Diphenhydramine 50 mg

Drug: Diphenhydramine 50 mg

2

EXPERIMENTAL

Diphenhydramine 25 mg

Drug: Diphenhydramine 25 mg

3

ACTIVE COMPARATOR

Pseudoephedrine 120 mg

Drug: Pseudoephedrine 120 mg

Interventions

Three times daily: two diphenhydramine 25 mg capsules Twice daily: one pseudoephedrine-matching placebo tablet

Also known as: Active: Lot # 070PB6 Formula # W015990-0002
1

Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule Twice daily: one pseudoephedrine-matching placebo tablet

Also known as: Active: Lot # 070PB6 Formula # W015990-0002
2

Three times daily: two diphenhydramine-matching placebo capsules Twice daily: one pseudoephedrine 120 mg tablet

Also known as: Active: Lot # INT-06-115 Formula # W015721-0004
3

Eligibility Criteria

Age12 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • otherwise healthy males and females
  • to 65 years of age
  • hypersensitivity to specific pollens for a minimum of 2 years prior to study start
  • appropriate SAR sign/symptoms scores

You may not qualify if:

  • pregnancy, lactation and contraception issues
  • contraindicated medications or therapies
  • evidence of clinical, dietary, lifestyle or psychiatric issues, which in the opinion of the investigator, could increase the risk to the subject or research staff, or interfere with the interpretation of study results

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Benchmark Research - Austin

Austin, Texas, 78705, United States

Location

Allergy and Asthma Associates

Austin, Texas, 78731, United States

Location

Lovelace Scientific Resources

Austin, Texas, 78759, United States

Location

Allergy/Immunology Research Center of North Texas

Dallas, Texas, 75230, United States

Location

Kerrville Research Associates

Kerrville, Texas, 78028, United States

Location

Central Texas Health Research

New Braunfels, Texas, 78130, United States

Location

Benchmark Research - San Angelo

San Angelo, Texas, 76904, United States

Location

Sun Research Institute

San Antonio, Texas, 78205, United States

Location

Biogenics Research Institute

San Antonio, Texas, 78229, United States

Location

Diagnostics Research Group

San Antonio, Texas, 78229, United States

Location

Sylvana Research Associates

San Antonio, Texas, 78229, United States

Location

Allergy Asthma Research Institute

Waco, Texas, 76712, United States

Location

MeSH Terms

Conditions

Nasal ObstructionRhinitis, Allergic, Seasonal

Interventions

DiphenhydraminePseudoephedrine

Condition Hierarchy (Ancestors)

Nose DiseasesRespiratory Tract DiseasesAirway ObstructionRespiratory InsufficiencyRespiration DisordersOtorhinolaryngologic DiseasesRhinitis, AllergicRhinitisRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

EthylaminesAminesOrganic ChemicalsBenzhydryl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPropanolaminesAmino AlcoholsAlcoholsPropanolsPhenethylamines

Study Officials

  • Melissa Israel, BS

    McNeil Consumer Healthcare Division of Mc-Neil-PPC, Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 20, 2008

First Posted

April 1, 2008

Study Start

November 1, 2006

Primary Completion

May 1, 2007

Study Completion

May 1, 2007

Last Updated

August 22, 2011

Record last verified: 2011-08

Locations